Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-RAD LABORATORIES, INC.BIO, BIOB · Entity 2247 | Executive Vice President | September 12, 2019 | September 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-RAD LABORATORIES, INC.
Report date September 12, 2019 · Filed September 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 18,728 |
Ending reported balance
After 2019-09-12 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2019-09-12 · Exercise / conversion · Acquired 600 · Balance 18,966 Row 2 · 2019-09-12 · Exercise / conversion · Acquired 600 · Balance 19,566 Row 3 · 2019-09-12 · Sale · Disposed 797 · Balance 18,769 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.00 to $328.70, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2019-09-12 · Sale · Disposed 41 · Balance 18,728 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $119.54 · Expires 2024-09-10 | Direct | 0 |
Reported balance
After 2019-09-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-09-12 · Exercise / conversion · Disposed 600 · Balance 0 F2: The option vests in five equal annual installments beginning September 10, 2015. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.56 · Expires 2025-09-11 | Direct | 600 |
Reported balance
After 2019-09-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-09-12 · Exercise / conversion · Disposed 600 · Balance 600 F3: The option vests in five equal annual installments beginning September 11, 2016. |
| Bio-Rad A Common StockSEC Table I · non-derivative | IndirectBy Spouse | 252 |
Reported balance
Holding disclosure · report date 2019-09-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 252 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.00 to $328.70, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The option vests in five equal annual installments beginning September 10, 2015.
F3: The option vests in five equal annual installments beginning September 11, 2016.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2019 Filed Sep 13, 2019 15:54 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 600 | $0.00 Strike: $139.56 | $0.00 |
DisclosureSEC source: 0001315406-19-000016 · edgar.xml · derivative · entry 7 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 600 shares Expires 2025-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in five equal annual installments beginning September 11, 2016. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 15:54 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 600 | $0.00 Strike: $119.54 | $0.00 |
DisclosureSEC source: 0001315406-19-000016 · edgar.xml · derivative · entry 6 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 600 shares Expires 2024-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in five equal annual installments beginning September 10, 2015. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 15:54 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 41 | $329.00 | $13,489.00 |
DisclosureSEC source: 0001315406-19-000016 · edgar.xml · nonDerivative · entry 4 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,728 Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 15:54 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 797 | $328.25 | $261,615.25 |
DisclosureSEC source: 0001315406-19-000016 · edgar.xml · nonDerivative · entry 3 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,769 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.00 to $328.70, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 15:54 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $139.56 | $83,736.00 |
DisclosureSEC source: 0001315406-19-000016 · edgar.xml · nonDerivative · entry 2 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 15:54 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $119.54 | $71,724.00 |
DisclosureSEC source: 0001315406-19-000016 · edgar.xml · nonDerivative · entry 1 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 15:48 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001315406-19-000014 · edgar.xml · derivative · entry 4 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 15:48 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 298 | $326.42 | $97,273.16 |
DisclosureSEC source: 0001315406-19-000014 · edgar.xml · nonDerivative · entry 2 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,366 Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 15:48 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-19-000014 · edgar.xml · nonDerivative · entry 1 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:07 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000063 · edgar.xml · derivative · entry 4 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:07 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 298 | $322.93 | $96,233.14 |
DisclosureSEC source: 0001652252-19-000063 · edgar.xml · nonDerivative · entry 2 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,064 Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:07 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000063 · edgar.xml · nonDerivative · entry 1 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 21:15 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 600 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-19-000059 · edgar.xml · derivative · entry 4 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Bio-Rad A Common Stock · 600 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests in five equal annual installments beginning September 7, 2017. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 21:15 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 444 | $336.47 | $149,392.68 |
DisclosureSEC source: 0001652252-19-000059 · edgar.xml · nonDerivative · entry 2 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,762 Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 21:15 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $159.32 | $95,592.00 |
DisclosureSEC source: 0001652252-19-000059 · edgar.xml · nonDerivative · entry 1 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · derivative · entry 23 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F14 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 7, 2017. F14 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 7, 2017. Read SEC document |
| September 07, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 298 | $335.59 | $100,005.82 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 15 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,606 Read SEC document |
| September 07, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 14 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 600 | $0.00 Strike: $326.15 | $0.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · derivative · entry 22 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Bio-Rad A Common Stock · 600 shares Expires 2028-09-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The option vests in five equal annual installments beginning September 4, 2019. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $215.98 | $0.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · derivative · entry 21 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Bio-Rad A Common Stock · 1,200 shares Expires 2027-09-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option vests in five equal annual installments beginning September 5, 2018. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · derivative · entry 20 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Bio-Rad A Common Stock · 1,200 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests in five equal annual installments beginning September 7, 2017. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,800 | $0.00 Strike: $139.56 | $0.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · derivative · entry 19 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Bio-Rad A Common Stock · 1,800 shares Expires 2025-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in five equal annual installments beginning September 11, 2016. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,400 | $0.00 Strike: $119.54 | $0.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · derivative · entry 18 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 2,400 shares Expires 2024-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in five equal annual installments beginning September 10, 2015. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 100 | $340.00 | $34,000.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 13 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,304 Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 543 | $338.97 | $184,060.71 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 12 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,404 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $338.63 to $339.17, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 750 | $338.01 | $253,507.50 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 11 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,947 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $337.63 to $338.44, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 1,231 | $336.80 | $414,600.80 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 10 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,697 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $336.36 to $337.20, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 1,871 | $335.64 | $627,982.44 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 9 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,928 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.32 to $336.24, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 700 | $334.77 | $234,339.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 8 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,799 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.29 to $335.22, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $326.15 | $195,690.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 7 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,200 | $215.98 | $259,176.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 6 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,200 | $159.32 | $191,184.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 5 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,800 | $139.56 | $251,208.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 4 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 2,400 | $119.54 | $286,896.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 3 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · derivative · entry 17 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F8 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 5, 2018. F8 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 5, 2018. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 208 | $339.48 | $70,611.84 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 2 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,299 Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 21:50 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000051 · edgar.xml · nonDerivative · entry 1 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 21:26 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000037 · edgar.xml · derivative · entry 4 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 4, 2019. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 4, 2019. Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 21:26 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 208 | $335.20 | $69,721.60 |
DisclosureSEC source: 0001652252-19-000037 · edgar.xml · nonDerivative · entry 2 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,907 Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 21:26 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000037 · edgar.xml · nonDerivative · entry 1 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 19:57 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000077 · edgar.xml · derivative · entry 5 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. F4 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 19:57 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000077 · edgar.xml · derivative · entry 4 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 11, 2014. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 11, 2014. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 19:57 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 523 | $308.37 | $161,277.51 |
DisclosureSEC source: 0001652252-18-000077 · edgar.xml · nonDerivative · entry 2 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,515 Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 19:57 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000077 · edgar.xml · nonDerivative · entry 1 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 20:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000058 · edgar.xml · derivative · entry 4 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 20:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 208 | $308.00 | $64,064.00 |
DisclosureSEC source: 0001652252-18-000058 · edgar.xml · nonDerivative · entry 2 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,738 Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 20:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000058 · edgar.xml · nonDerivative · entry 1 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 18:02 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000043 · edgar.xml · derivative · entry 4 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 7, 2017. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 7, 2017. Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 18:02 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 208 | $313.74 | $65,257.92 |
DisclosureSEC source: 0001652252-18-000043 · edgar.xml · nonDerivative · entry 2 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,346 Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 18:02 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000043 · edgar.xml · nonDerivative · entry 1 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.